Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.

Lena-Christin ConradiMelanie SpitznerAnna-Lena MetzgerMerle KislyPeter MiddelHanibal BohnenbergerJochen GaedckeMichael B GhadimiTorsten LierschJoseph RüschoffTim BeißbarthAlexander KönigMarian Grade

Published in: BMC cancer (2019)

Since HER-2 and HER-3 are expressed in a relevant number of patients, targeting both receptors may represent a promising therapeutic strategy for CRC.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
cancer therapy
peritoneal dialysis